Outline
• Welcome and objectives
• Microbiology, epidemiology and clinical presentation
• Surveillance for imported cases including case definitions
• Laboratory diagnosis • Infection prevention and hospital readiness
• Patient flow and actions required at each step
• Co-ord...inating a public health response
more
Laboratory Biossafety Manual
Временное руководство
19 марта 2020 г.
Данный документ предоставляет временное руководство лабораториям и заинтересованным сторонам, участвующим в лабораторном �...�естировании пациентов с вирусом COVID-19.
Документ частично основан на временном руководстве по лабораторному тестированию на коронавирус, вызывающий ближневосточный респираторный синдром (MERS).1-6 Информация о заражении человека вирусом COVID-19 постоянно обновляется, ВОЗ продолжает следить за развитием событий и по необходимости пересматривать рекомендации.
more
Временные рекомендации 25 января 2020 г.
Timely detection of novel coronavirus (2019-nCoV) infection cases is crucial to interrupt the spread of this virus. We assessed the required expertise and capacity for molecular detection of 2019-nCoV in specialised laboratories in 30 European Union/European Economic Area (EU/EEA) countries. Thirty-...eight laboratories in 24 EU/EEA countries had diagnostic tests available by 29 January 2020. A coverage of all EU/EEA countries was expected by mid-February. Availability of primers/probes, positive controls and personnel were main implementation barriers.
more
(7th Version)
20, March 2020
Временные рекомендации
13 марта 2020 г.
Настоящий документ является вторым изданием руководства (версия 1.2), которое первоначально представляло собой адаптированн...ый вариант Руководства по клиническому ведению тяжелой острой респираторной инфекции при подозрении на инфекцию MERS-CoV (ВОЗ, 2019 г.).
more
Objetivos
• Los dispositivos médicos enumerados en este documento proporcionan estándares mínimos y descripciones técnicas y especificaciones de dispositivos médicos para el tratamiento de soporte de COVID-19.§ • Estos dispositivos médicos no son limitados y son adaptables a todos los p...aíses de la región, independientemente de sus diferentes sistemas de atención médica y disparidades socioeconómicas. Además, se recomiendan para: o Terapia de soporte temprana y monitoreo de infecciones respiratorias agudas graves (IRAG) cuando se sospecha de infección por COVID-19; o Tratamiento de la insuficiencia respiratoria hipoxémica y el síndrome de dificultad respiratoria aguda (SDRA) en pacientes con COVID-19; o Manejo del shock séptico en pacientes con COVID-19.
more
This document provides guidance on the application of non-pharmaceutical countermeasures to minimise the spread of the 2019 novel coronavirus (2019-nCoV) in the population. Some of the measures proposed refer specifically to certain phases of the epidemic (containment or mitigation phases), and can ...be adapted depending on the assessed severity/impact of the infection. Other measures are valid for all phases of an epidemic.
The guidance is based on the current knowledge of the 2019-nCoV and evidence available on other viral respiratory pathogens, mainly the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), the Middle East Respiratory Syndrome-related coronavirus (MERS-CoV) and seasonal or pandemic influenza viruses.
more
Nota INformatIva Nº 13/2020 - SE/GaB/SE/mS
September 2020
23 Dec 2020. The aim of this document is to provide an update on the knowledge surrounding the role of children in the transmission of SARS-CoV-2 and the role of schools in the COVID-19 pandemic, based on the experience in the EU from August–December, 2020. This document also addresses transmissio...n to and from staff in school settings, school-related mitigation measures including risk communication, testing, contact tracing and the efficacy of partial and full school closures. This document draws upon and updates evidence presented in the previous report from ECDC on this topic, which was published on August 6, 2020
more
August 2020, The Africa Joint Continental Strategy for COVID-19 is underpinned by the need to limit transmission, prevent deaths and reduce associated harms. Participation by African nations in clinical trials is an essential step to ensure that sufficient data is generated on the safety and efficac...y of the most promising vaccine candidates among the region’s populations.
While current COVID-19 clinical trial activity on the continent is limited, Africa has substantial experience and capabilities to conduct clinical trials for preventative vaccines across a range of diseases, and many organizations on the continent are working tirelessly to help prepare additional trials on potential COVID-19 vaccines. As the number of candidate vaccines in the development pipeline continues to increase, it will be important for organizations responsible for managing clinical trials in the region to partner with vaccine developers to identify potential and appropriate trial locations, provide support to remove any critical obstacles impeding commencement and progress of trials, and to provide oversight ensuring that trials are conducted safely and ethically.
more
This document is intended to guide the care of COVID-19 patients as the response capacity of health systems is challenged; to ensure that COVID-19 patients can access life-saving treatment, without compromising public health objectives and safety of health workers.
It promotes two key messages:
...
1. Key public health interventions regardless of transmission scenario; and
2. Key action steps to be taken by transmission scenario to enable timely surge of clinical operations.
more
Временные рекомендации23апреля 2020г.
doi: https://doi.org/10.1101/2020.10.28.20221143
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.